Table 2.
Univariable and Multivariable Analysis With Sustained Virologic Response 12 Weeks After Completion
| Factors | Univariate (Unadjusted) | Multivariate (Adjusted) | ||||
|---|---|---|---|---|---|---|
| OR | 95% CI | P Value | OR | 95% CI | P Value | |
| Age, yr | 0.99 | 0.94–1.05 | .70 | 0.98 | 0.90–1.06 | .71 |
| Gender, female | 1.87 | 0.74–4.74 | .19 | 1.67 | 0.42–6.68 | .46 |
| Race, black | 2.28 | 0.80–6.52 | .12 | 1.97 | 0.46–8.50 | .36 |
| HCV genotype, 1a | 0.48 | 0.29–1.17 | .11 | 0.28 | 0.13–1.31 | .11 |
| Body mass index (kg/m2) | 1.06 | 0.96–1.16 | .24 | 1.03 | 0.93–1.14 | .62 |
| Treatment naive | 2.89 | 1.18–7.07 | .02 | 6.93 | 2.61–10.4 | .01 |
| CD4 <200 cells/µL | 0.69 | 0.18–2.62 | .58 | 0.27 | 0.32–2.24 | .23 |
| HIV-1 RNA <40 copies/mL | 1.08 | 0.23–5.11 | .93 | 0.74 | 0.06–9.41 | .81 |
| HCV RNA (IU/mL) | 1.00 | 0.99–1.01 | .95 | 1.00 | 0.99–1.01 | .99 |
| Fib-4 score ≥3.25 | 0.79 | 0.29–2.15 | .65 | 0.52 | 0.12–2.22 | .38 |
| Platelets, ×103/µL | 1.00 | 0.99–1.00 | .39 | 0.99 | 0.98–1.00 | .06 |
| ALT | 1.00 | 0.99–1.01 | .82 | 1.01 | 0.98–1.04 | .50 |
| AST | 0.99 | 0.98–1.01 | .20 | 0.98 | 0.96–0.99 | .04 |
Abbreviations; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CI, confidence interval; Fib, fibrosis; HCV, hepatitis C virus; HIV, human immunodeficiency virus; OR, odds ratio; RNA, ribonucleic acid.